Bluebird bio, Inc.
BLUE
Rang in Aktien
#15675
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Aktienkurs
$4.97
Zuletzt synchronisiert: 2025-06-02
Marktkapitalisierung
$318.62M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-38.03%
Land
US
Handel Bluebird bio, Inc. (BLUE)
Kategorie
Healthcare
Marktkapitalisierung von Bluebird bio, Inc.(BLUE)
Marktkapitalisierung: $318.62M
Mit Stand October 2026 hat Bluebird bio, Inc. eine Marktkapitalisierung von $318.62M. Das macht Bluebird bio, Inc. laut unseren Daten zum 15675th wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von Bluebird bio, Inc. von 2018 bis 2026
BLUE im Vergleich zu den Top 5 der beliebtesten stocks
